CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Unlike that noted in K562 cells, MSDC-0160 reduced both total glucose contribution and m + 3 contribution to TCA cycle metabolites in a dose-dependent manner in primary CML CD34+ samples (Fig. 4e and Supplementary Fig. S4C).